2023 World Conference on Lung Cancer (Posters)-P1.22. ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments

P1.22. ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments - PDF(Slides)

Back to course

Pdf Summary

Immunotherapy-based treatments are commonly used for advanced non-small-cell lung cancer (NSCLC) patients who cannot undergo targeted therapies. However, some patients do not respond well to these treatments, and there is currently no effective method to predict patient outcomes. In this study, the researchers aimed to identify biomarkers that could predict patient outcomes by analyzing tumor molecular alterations before immunotherapy-based treatments.<br /><br />The researchers collected and processed samples from NSCLC patients and performed next-generation sequencing to analyze the molecular profiling of the tumors. The results showed that certain alterations in the BRAF and ERBB3 genes could impact patient outcomes. Pathogenic variants in BRAF were found to be a good prognostic factor in stage IV NSCLC patients treated with immunotherapy or chemo-immunotherapy. On the other hand, pathogenic mutations in ERBB3 were associated with a higher risk of disease progression.<br /><br />While these findings suggest that BRAF and ERBB3 mutations may serve as potential biomarkers for predicting patient outcomes in NSCLC under immunotherapy-based treatments, further studies with larger cohorts of patients are needed to confirm these hypotheses.<br /><br />This study provides valuable insights into the potential use of molecular alterations as biomarkers for predicting patient outcomes in NSCLC under immunotherapy-based treatments. Identifying biomarkers that can accurately predict patient responses to these treatments could help personalize treatment plans and improve patient outcomes.

Asset Subtitle

Lucía Robado de Lope

Meta Tag

Speaker Lucía Robado de Lope

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

Immunotherapy-based treatments

non-small-cell lung cancer

NSCLC

targeted therapies

patient outcomes

biomarkers

tumor molecular alterations

BRAF gene

ERBB3 gene

prognostic factors